LinkedIn YouTube Bluesky
Search
EN / FR
Ethics Portal
  • Who We Are
      • Who We Are
      • About Us
      • Business Model
      • Our Strategy 2023-2025
      • Statutes, By-Laws & Policies
      • Governance & Team
      • Annual Reports
      • Careers & RFPs
  • What We Do
      • What We Do
      • Licensing for Public Health
      • mRNA Technology Transfer Programme
      • Disease Areas
      • Addressing Children’s Needs
      • Prioritising Medicines for Licensing
      • Long-Acting Therapeutics
      • Focus areas
      • Biotherapeutics
      • Local and Regional Manufacturing
      • Pandemic Preparedness and Response
      • Upstream Access
      • Technology Transfer
      • Patent Information Tools
      • MedsPaL
      • LAPaL
  • Progress
      • Progress
      • Licences
      • Prioritisation
      • Agreements with Innovators
      • Access to Medicines Tracker
      • Contribution to Universal Health Coverage
      • Endorsements
      • Impact
  • News & Publications
      • News
        & Publications
      • News, Events & Press Releases
      • Messages from the Executive Director
      • MPP in the Media
      • MPP Publications
      • Related Publications
      • Newsletters & Updates
  • Partners
      • Partners
      • Partnering with MPP
      • Funders
      • Our Stories
      • Voices from Friends of MPP
      • Voices from the Frontline
      • I am part of the DTG story
      • How to Give or Get a Licence
  • Contact Us
EN / FR
Ethics Portal
Search

EXPERT ADVISORY GROUP REPORTS

  • EAG report on WHO and MPP agreements with NIH for 11 COVID-19 health technologies
  • EAG report on UW’s long-acting injectable HIV drug combination technology
  • EAG report on CSIC’s ELISA antibody technology (diagnostic test)
  • EAG report on Pfizer’s PF-07321331
  • EAG report on MSD’s molnupiravir
  • EAG report on ViiV’s dolutegravir for upper-middle-income countries: Azerbaijan, Belarus, Kazakhstan and Malaysia
  • EAG report on Pfizer’s sutezolid
  • EAG report on Gilead’s bictegravir
  • EAG report on AbbVie’s lopinavir, ritonavir for Africa
  • EAG report on AbbVie’s LPV/r paediatric
  • EAG report on Bristol-Myers Squibb’s daclatasvir
  • EAG report on Bristol-Myers Squibb’s atazanavir
  • EAG report on the proposed amendments to the MPP-Gilead agreement to incorporate TAF
  • EAG report on the Johns Hopkins University’s sutezolid
  • EAG report on MSD’s raltegravir paediatric
  • EAG report on Pharco’s ravidasvir
  • EAG report on the proposed collaboration with Roche
  • EAG report on the University of Liverpool’s solid drug nanoparticle technology
  • EAG report on ViiV Heathcare’s dolutegravir
  • EAG report on the proposed paediatric collaboration with ViiV Heathcare
Share page:
Facebook
Linkedin
Bluesky

Contact Us

Legal

Related page

Governance & Team

About Us

The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.

To date, MPP has signed agreements with 22 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.

MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada, the World Intellectual Property Organization (WIPO) and the Government of Flanders. MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, and SDC.

MPP Logo
  • About Us
  • MedsPaL
  • licences
  • Careers & RFPs
  • Privacy Policy
Follow us
LinkedIn YouTube Bluesky

Founded & funded by

Unitaid Logo

Other funders

Designed and built by ACW